Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATTICE-UC: Deucravacitinib in Moderate to Severe Ulcerative Colitis
NCT03934216Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: Clinical Remission Response Rate at 12 weeks. Started Jul 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03934216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934216.